|
Malignant neoplasm of ovary
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A total of 1,195 patients, including 719 patients with breast cancer and 240 with ovarian cancer, were tested, and four (~0.3%) had the truncating mutation in PPM1D.
|
31242196 |
2019 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overall, the findings of the present study suggest that targeting Wip1 may be a potential therapeutic avenue for the treatment of human ovarian cancer in the future.
|
28440479 |
2017 |
|
Malignant neoplasm of ovary
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The frequency of somatic mosaic PPM1D mutations in PBMCs was significantly associated with prior chemotherapy (P < .001), and, in patients exposed to chemotherapy, with older age at blood draw (recurrent OC odds ratio [OR], 17.24; 95% CI, 6.80-43.69; and primary OC postchemotherapy OR, 4.82; 95% CI, 1.43-16.18).
|
26847329 |
2016 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
PPM1D Mosaic Truncating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations.
|
26823519 |
2016 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
To illustrate the role of PPM1D in gynecological cancer cell chemoresistance and its regulation by Akt we have demonstrated that: (a) CDDP induced PPM1D down-regulation through proteasomal degradation in sensitive CECA cells; (b) CDDP induced PPM1D nuclear localization in resistant CECA cells, and nuclear exclusion in sensitive CECA cells and OVCA xenografts; (c) Over-expression of active Akt in sensitive CECA cells stabilized PPM1D content through inhibition of CDDP-induced PPM1D down-regulation; (d) Inhibition of Akt activity in resistant OVCA cells leads to decreased PPM1D stability and CDDP-induced down-regulation in resistant CECA cells; and (e) PPM1D is highly expressed in human ovarian tumor subtypes and in a tissue microarray panel of human ovarian tumors.
|
25154814 |
2015 |
|
Malignant neoplasm of ovary
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These observations suggest PPM1D mutations in the mosaic state predispose women to breast and ovarian cancer in the absence of a family history of cancer.
|
24262437 |
2014 |
|
Malignant neoplasm of ovary
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Protein phosphatase magnesium-dependent 1δ (PPM1D) is an oncogene, overexpressed in many solid tumors, including ovarian cancer and breast cancer.
|
23556002 |
2013 |
|
Malignant neoplasm of ovary
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer.
|
23242139 |
2013 |
|
Malignant neoplasm of ovary
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Here, using pair-matched wild-type p53 CDDP-sensitive (OV2008) and -resistant (C13*) cells, and p53-compromised CDDP-resistant cells (A2780cp, OCC-1, OVCAR-3 and SKOV3), we have demonstrated (i) the existence of site-specific differences in phospho-Ser-Chk1 content between sensitive and resistant cells in response to CDDP; (ii) PPM1D, but not phosphoinositide-3-kinase-related kinase Ataxia Telangiectasia and Rad3 related protein (ATR), is important in the regulation of CDDP-induced Chk1 activation and OVCA cell chemosensitivity; (iii) PPM1D downregulation sensitizes resistant cells to CDDP primarily by activating Chk1 and p53.
|
21927021 |
2012 |
|
Malignant neoplasm of ovary
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Moreover, the Wip1 gene may be amplified or overexpressed, especially in hormone-regulated organs, and Wip1 gene amplification has been correlated with poor prognosis in hormone-related malignancies, including ovarian cancers.
|
19435816 |
2009 |